Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)
Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Martin Jimenez M, Nusch A, Sonke GS, De La Cruz Merino L, Beck JT, Zarate JP, Wang Y, Chakravartty A, Wang C, Slamon D (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S194-S194
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2022.03.280
Authors with CRIS profile
Involved external institutions
Masaryk Memorial Cancer Institute (MMCI) / Masarykův onkologický ústav (MOÚ)
Czech Republic (CZ)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Hospital General Universitario Gregorio Marañón
Spain (ES)
Netherlands Cancer Institute (NKI)
Netherlands (NL)
Hospitales Universitarios Virgen Macarena y Virgen del Rocío
Spain (ES)
Highlands Oncology Group
United States (USA) (US)
Novartis Pharma Germany
Germany (DE)
Novartis AG
Switzerland (CH)
University of California Los Angeles (UCLA)
United States (USA) (US)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
BC Cancer
Canada (CA)
University of Liège (ULg) / Université de Liège
Belgium (BE)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Italy (IT)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
Czech Republic (CZ)
Fondazione IRCCS: Istituto Nazionale dei Tumori
Italy (IT)
Hospital General Universitario Gregorio Marañón
Spain (ES)
Netherlands Cancer Institute (NKI)
Netherlands (NL)
Hospitales Universitarios Virgen Macarena y Virgen del Rocío
Spain (ES)
Highlands Oncology Group
United States (USA) (US)
Novartis Pharma Germany
Germany (DE)
Novartis AG
Switzerland (CH)
University of California Los Angeles (UCLA)
United States (USA) (US)
University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven
Belgium (BE)
BC Cancer
Canada (CA)
University of Liège (ULg) / Université de Liège
Belgium (BE)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Italy (IT)
Seoul National University (SNU) / 서울대학교
Korea, Republic of (KR)
How to cite
APA:
Neven, P., Fasching, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A.,... Slamon, D. (2022). Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL). In ANNALS OF ONCOLOGY (pp. S194-S194). AMSTERDAM: ELSEVIER.
MLA:
Neven, P., et al. "Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL)." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S194-S194.
BibTeX: Download